SCHEMBL4671828

SCHEMBL4671828

O=C(O)C(O)=CC(=O)c1csc(S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.43
ALDH1A1 P00352 3/20 0.37
NPSR1 Q6W5P4 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MMP8 P22894 2/20 0.35
MMP3 P08254 1/20 0.35
HTR6 P50406 1/20 0.35
HSD11B1 P28845 1/20 0.34
NFE2L2 Q16236 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
MAOA P21397 1/20 0.33
LOX P28300 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
ACLY P53396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671823 1.00 CA2 (0.43) CA2ALDH1A1NPSR1GAAMAPT
SCHEMBL4672592 0.88 PTGS2 (0.38) CA2MAPTHSD11B1
SCHEMBL4672596 0.88 PTGS2 (0.38) CA2MAPTHSD11B1
SCHEMBL4674904 0.88 AKR1C3 (0.38) CA2ALDH1A1MAPTHSD11B1KDM4E
SCHEMBL4674900 0.88 AKR1C3 (0.38) CA2ALDH1A1MAPTHSD11B1KDM4E
SCHEMBL4675381 0.76 HTR6 (0.40) CA2ALDH1A1NPSR1GAAMAPT
SCHEMBL4675379 0.76 HTR6 (0.40) CA2ALDH1A1NPSR1GAAMAPT
SCHEMBL4677875 0.74 LOX (0.44) ALDH1A1NPSR1GAAMAPTSMN1; SMN2
SCHEMBL4677872 0.74 LOX (0.44) ALDH1A1NPSR1GAAMAPTSMN1; SMN2
SCHEMBL4675093 0.74 ALDH1A1 (0.36) ALDH1A1NPSR1GAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CA2 2384/4885ALDH1A1 980/4885NPSR1 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.